Cargando…

Impact of Combined mTOR and MEK Inhibition in Uveal Melanoma Is Driven by Tumor Genotype

Uveal melanomas possess activation of the mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K)/AKT/mammalian Target of Rapamycin (mTOR) pathways. MAPK activation occurs via somatic mutations in the heterotrimeric G protein subunits GNAQ and GNA11 for over 70% of tumors and le...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ho, Alan L., Musi, Elgilda, Ambrosini, Grazia, Nair, Jayasree S., Deraje Vasudeva, Shyamprasad, de Stanchina, Elisa, Schwartz, Gary K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3393714/ https://www.ncbi.nlm.nih.gov/pubmed/22808163 http://dx.doi.org/10.1371/journal.pone.0040439

Ejemplares similares

BRD4-targeted therapy induces Myc-independent cytotoxicity in Gnaq/11-mutatant uveal melanoma cells
por: Ambrosini, Grazia, et al.
Publicado: (2015)

The GPER Agonist LNS8801 Induces Mitotic Arrest and Apoptosis in Uveal Melanoma Cells
por: Ambrosini, Grazia, et al.
Publicado: (2023)

Intermittent MEK inhibition for the treatment of metastatic uveal melanoma
por: Khan, Shaheer, et al.
Publicado: (2022)

Transcriptional analysis of metastatic uveal melanoma survival nominates NRP1 as a therapeutic target
por: Bao, Riyue, et al.
Publicado: (2020)

Co-Targeting FASN and mTOR Suppresses Uveal Melanoma Growth
por: Han, Anna, et al.
Publicado: (2023)

A Phase Ib Study of Sotrastaurin, a PKC Inhibitor, and Alpelisib, a PI3Kα Inhibitor, in Patients with Metastatic Uveal Melanoma
por: Shoushtari, Alexander N., et al.
Publicado: (2021)

Tris DBA palladium is an orally available inhibitor of GNAQ mutant uveal melanoma in vivo
por: Musi, Elgilda, et al.
Publicado: (2019)

Significant blockade of multiple receptor tyrosine kinases by MGCD516 (Sitravatinib), a novel small molecule inhibitor, shows potent anti-tumor activity in preclinical models of sarcoma
por: Patwardhan, Parag P., et al.
Publicado: (2015)

Monosomy 3 Is Linked to Resistance to MEK Inhibitors in Uveal Melanoma
por: Mergener, Svenja, et al.
Publicado: (2021)

HDAC11 activity contributes to MEK inhibitor escape in uveal melanoma
por: Sriramareddy, Sathya Neelature, et al.
Publicado: (2022)

Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR Pathway
por: Atefi, Mohammad, et al.
Publicado: (2011)

Mutant HRAS as novel target for MEK and mTOR inhibitors
por: Kiessling, Michael K., et al.
Publicado: (2015)

Histone deacetylase inhibitors: a promising partner for MEK inhibitors in uveal melanoma?
por: Faião-Flores, Fernanda, et al.
Publicado: (2019)

Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma
por: Wang, Beike, et al.
Publicado: (2021)

PTK6 inhibits autophagy to promote uveal melanoma tumorigenesis by binding to SOCS3 and regulating mTOR phosphorylation
por: Liu, Bo, et al.
Publicado: (2023)

Combination MEK and mTOR inhibitor therapy is active in models of glioblastoma
por: Schreck, Karisa C, et al.
Publicado: (2020)

A phase Ib trial of combined PKC and MEK inhibition with sotrastaurin and binimetinib in patients with metastatic uveal melanoma
por: Bauer, Sebastian, et al.
Publicado: (2023)

Artemisinin Inhibits the Migration and Invasion in Uveal Melanoma via Inhibition of the PI3K/AKT/mTOR Signaling Pathway
por: Farhan, Mohd, et al.
Publicado: (2021)

MITF deficiency accelerates GNAQ-driven uveal melanoma
por: Phelps, Grace B., et al.
Publicado: (2022)

KDOAM-25 Overcomes Resistance to MEK Inhibitors by Targeting KDM5B in Uveal Melanoma
por: Zhang, Hongjun, et al.
Publicado: (2022)

The mTOR inhibitor Everolimus synergizes with the PI3K inhibitor GDC0941 to enhance anti-tumor efficacy in uveal melanoma
por: Amirouchene-Angelozzi, Nabil, et al.
Publicado: (2016)

PI3K/AKT/mTOR pathway-derived risk score exhibits correlation with immune infiltration in uveal melanoma patients
por: Geng, Yuxin, et al.
Publicado: (2023)

Overcoming mTOR Resistance Mutations with a New Generation mTOR Inhibitor
por: Rodrik-Outmezguine, Vanessa S., et al.
Publicado: (2016)

Stromal fibroblast growth factor 2 reduces the efficacy of bromodomain inhibitors in uveal melanoma
por: Chua, Vivian, et al.
Publicado: (2019)

FAK Inhibitor-Based Combinations with MEK or PKC Inhibitors Trigger Synergistic Antitumor Effects in Uveal Melanoma
por: Tarin, Malcy, et al.
Publicado: (2023)

Retracted: KDOAM-25 Overcomes Resistance to MEK Inhibitors by Targeting KDM5B in Uveal Melanoma
por: International, BioMed Research
Publicado: (2023)

The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition
por: Haagensen, E J, et al.
Publicado: (2012)

Combined inhibition of MEK and mTOR has a synergic effect on angiosarcoma tumorgrafts
por: ANDERSEN, NICHOLAS J., et al.
Publicado: (2015)

Dose‐Dependent Carbon‐Dot‐Induced ROS Promote Uveal Melanoma Cell Tumorigenicity via Activation of mTOR Signaling and Glutamine Metabolism
por: Ding, Yi, et al.
Publicado: (2021)

Elevated ZNF704 expression is associated with poor prognosis of uveal melanoma and promotes cancer cell growth by regulating AKT/mTOR signaling
por: Luo, Jingting, et al.
Publicado: (2023)

Uveal Melanoma
por: Papastefanou, Vasilios P., et al.
Publicado: (2011)

Uveal Melanoma
por: Pfeffer, Ulrich
Publicado: (2019)

Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines
por: von Euw, Erika, et al.
Publicado: (2012)

Adjuvant crizotinib in high-risk uveal melanoma following definitive therapy
por: Khan, Shaheer, et al.
Publicado: (2022)

mTOR Inhibition Induces Compensatory, Therapeutically Targetable MEK Activation in Renal Cell Carcinoma
por: Bailey, Sean T., et al.
Publicado: (2014)

Combined mTOR and MEK inhibition is an effective therapy in a novel mouse model for angiosarcoma
por: Chadwick, Michelle L., et al.
Publicado: (2018)

Combined Treatment with MEK and mTOR Inhibitors is Effective in In Vitro and In Vivo Models of Hepatocellular Carcinoma
por: Liu, Xianqiong, et al.
Publicado: (2019)

MRI of Uveal Melanoma
por: Ferreira, Teresa A., et al.
Publicado: (2019)

The biology of uveal melanoma
por: Amaro, Adriana, et al.
Publicado: (2017)

Uveal Melanoma Metastasis
por: Rossi, Ernesto, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_jr199fkqdnb9hn0897uqdprit5